Analysts See Daiichi Weathering Ranbaxy Merger Fallout
This article was originally published in PharmAsia News
Daiichi Sankyo's beginnings as the parent of Ranbaxy Laboratories of India is costing the Japanese firm in the short run, but the deal still is expected to be beneficial in the long run, according to analysts. Since acquiring Ranbaxy, Daiichi has seen its shares under pressure because of problems with two of the Indian drug maker's factories that led to a temporary U.S. ban on its products. Analysts expect Daiichi to weather the fallout and become more stable with Ranbaxy as a subsidiary. (Click here for more - a subscription may be required
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.